EGFR and non-small cell lung carcinoma: In addition, adjuvant therapy with PD-L1 inhibitors has been introduced for resectable NSCLC and unresectable stage III NSCLC; however, EGFR-positive NSCLC is unlikely to benefit from ICI, even in these patients, and targeted therapy seems to be the most promising.